SecBot SecBot
SECBOTREPLAY Home › Report › CCCC

CCCC · C4 Therapeutics reported Q1 2026 results with an EPS beat ($-0.18 vs…

C4 Therapeutics, Inc. · PRESS-RELEASE filed May 12, 2026 at 07:00 ET

At the news

MIXEDIMPACT 5/10

PRESS-RELEASE filed May 12, 2026 at 07:00 ET

C4 Therapeutics reported Q1 2026 results with an EPS beat ($-0.18 vs $-0.26 consensus) and revenue beat ($6.2M vs $4.4M consensus), but total revenue declined 15% YoY from $7.2M. The company highlighted clinical progress for cemsidomide and a new Roche collaboration, with a cash runway to end of 2028. The mixed earnings beat and pipeline catalysts are offset by the revenue decline.

  • Q1 2026 revenue $6.152 million, down from $7.238 million YoY
  • Net loss per share $-0.20, improved from $-0.37 YoY
  • Beat consensus EPS ($-0.26) and revenue ($4.4M)
  • Cash & equivalents $268.3 million; runway to end of 2028

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access